检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]中山大学附属第六医院消化内科,广州市510655 [2]广州市中医医院麻醉科,510130
出 处:《实用医学杂志》2011年第15期2701-2703,共3页The Journal of Practical Medicine
基 金:国家自然科学基金资助项目(编号:30600845);广东省卫生厅资助项目(编号:B2006135);佛山市科技局基金(编号:200608001)
摘 要:目的:研究水飞蓟宾对非酒精性脂肪性肝病(NAFLD)大鼠血清、肝脏、脂肪组织、骨骼肌中脂联素及抵抗素基因水平表达的影响,探讨水飞蓟宾防治NAFLD的可能作用机制。方法:通过6周高脂饮食建立NAFLD大鼠模型,采用水飞蓟宾进行干预,与已知有疗效的罗格列酮比较,用ELISA及Realtime-PCR等方法检测各组大鼠血清、肝脏、脂肪组织以及骨骼肌中脂联素和抵抗素的表达水平。结果:药物干预后大鼠血清、肝脏、脂肪组织中脂联素基因表达水平较模型组升高,抵抗素基因表达水平下降(P<0.05)。水飞蓟宾对血清及脂肪组织脂联素的表达促进作用优于罗格列酮,对于肝脏脂联素表达的促进作用逊于罗格列酮(P<0.05)。骨骼肌中脂联素及抵抗素表达水平极低,高脂饮食以及药物干预对其影响无统计学差异。结论:水飞蓟宾有效地促进脂联素表达,抑制抵抗素表达,这可能是其防治NAFLD的作用机制之一。Objective To investigate the gene expression of adiponectin and resistin in serum, liver tissue, adipose tissue as well as skeletal muscles in nonalcoholic fatty liver disease (NAFLD) rats with the aim to figure out the possible mechanism of silybin on NAFLD rats. Methods Rat models of NAFLD were established by high fat diet for 6 weeks. Silybin and rosiglitazone were used as pharmaceutic intervention. Serum levels of adiponectin and resistin were detected by ELISA. The gene expression of adiponectin and resistin were measured by Real-time PCR. Results Rise in the gene expression of adiponectin and decline in that of resistin were observed in silybin and rosiglitazone group (P 〈 0.05). Silybin was superior to rosiglitazone on enhancing expression of adiponectin in serum and liver, but inferior on enhancing expression of adiponectin in adipose tissue (P 〈 0.05). Adiponectin and resistin had a low level of gene expression in skeletal muscles and had no significant difference between model group and the two intervened groups. Conclusions Modulating expression of adipocytokines is probably one of the mechanisms for hepatoprotective effect of silybin in the nonalcoholic fatty liver disease.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.3